Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
SEEGENE

Rapid Diagnostic Tests Compared for Invasive Amoebiasis

By Labmedica International staff writers
Posted on 30 Oct 2013
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Three rapid immunoassays have been compared and evaluated for the diagnosis of invasive amoebiasis in an emergency department.

Sensitive rapid diagnostic tests (RDT) contribute to an early diagnosis and thus improve the prognosis. The test should be also specific to distinguish amoebic and pyogenic abscess in order to avoid a percutaneous drainage for diagnostic purposes and a broad-spectrum antibiotherapy.

Scientists at the Military Teaching Hospital (HIA) Bégin (Saint-Mandé, France) carried out a retrospective biological records review that included 639 patients for whom three serological tests were performed. They compared a latex agglutination test (LAT) with enzyme-linked immunosorbent assay and indirect hemagglutination assay in the diagnosis of invasive amoebiasis (IA) performed from January 1, 2001, to July 1, 2012.

The three different techniques performed for each patient at laboratory of Bégin Hospital were: a latex agglutination slide test (LAT) (Bichrolatex-Amibe, Fumouze Diagnostic; Levallois-Perret, France); an enzyme linked immunosorbent assay (ELISA) (NovaTec Entamoeba histolytica IgG-ELISA, DiaSorin SPA; Saluggia, Italy); and the Fumouze Diagnostic’s indirect hemagglutination assay Amibiase HAI (IHA).

A total of 639 patients with a performed serology were included and among them 75 had at least one positive serological result. Of these 75 patients, 46 had a final diagnosis of IA, 43 with hepatic amoebiasis, two with intestinal amoebomas and one with pleuropulmonary amoebiasis and 29 patients had another final diagnosis. The LAT was statistically more sensitive than ELISA and IHA.

The authors concluded that LAT could be used in any routine clinical laboratory because it is simple to perform and does not require any special equipment. The result is achieved quickly in 15 minutes. The interpretation is easy because the bicolored positive pattern is very distinguishable from a negative brown spot. The cost remains low at approximately EUR 5.22 per test in France. The LAT is a useful screening technique in the rapid diagnosis and the management of patients with febrile hepatalgia in emergency units. However, this test should be systematically confirmed by reference techniques (ELISA, IHA). The study was published on October 11, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Military Teaching Hospital Bégin
Fumouze Diagnostic 
DiaSorin SPA 



ADVANCED INSTRUMENTS
PURITAN MEDICAL
GREINER-BIO-ONE
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.